A Comparison of Three Different Formulations of Topical Prednisolone Acetate 1% for Control of Post Glaucoma and/or Cataract Surgery Inflammation.
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- Percent Change in Flare at Resolution
研究概览
简要总结
Generic prednisolone acetate 1% is less effective than Pred Forte 1% or Econopred Plus 1%.
详细描述
Overall Study Design:
Structure:
This is a randomized, double-masked prospective study. The study medications will be masked and randomized by the outpatient pharmacy at Indiana University Hospital.
Duration:
Treatment duration: The duration of each subject's participation will be for up to 2 months after surgery. One hundred and two subjects will be enrolled over a twelve-month time span.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Be willing and able to provide written informed consent.
- •Be able and willing to follow instructions on the use of the study medication and likely to complete the entire course of the study.
- •Be male or female of any race at least 18 years of age.
- •Have visually significant cataract or medically uncontrolled glaucoma for which they have elected to undergo surgery.
排除标准
- •Contraindication to use of corticosteroids.
- •Ocular disease other than glaucoma or ocular hypertension that would interfere with study parameters (such as: uveitis, ocular infection, or severe dry eye). Subjects with mild chronic blepharitis, age-related macular degeneration and background diabetic retinopathy may be enrolled at the discretion of the investigator.
- •Laser or any other intraocular surgery within the past three months.
- •Require use of ocular NSAID or systemic steroids.
- •Have known allergy or sensitivity to the study medications or their components
- •Have corneal abnormalities that would interfere with the ability to obtain an adequate laser flare measurement.
- •Be concurrently enrolled in an investigational drug or device study or participation within the last 30 days in any investigational drug or device study.
- •Be pregnant, nursing, planning a pregnancy, or be of childbearing potential and not using a reliable form of contraception (a woman is considered of childbearing potential unless she is postmenopausal, has had a uterus and/or both ovaries removed, or has had a bilateral tubal ligation).
- •Have a situation or condition that in the investigator's opinion may put the subject at significant risk, may confound the study results, or may interfere significantly with participation in the study
研究组 & 干预措施
Pred Forte 1%
Pred Forte 1% dosed four times daily decreasing to once daily over four weeks.
干预措施: Pred Forte (Drug)
EconoPred Plus 1%
EconoPred Plus 1% dosed four times daily decreasing to once daily over four weeks.
干预措施: EconoPred Plus (Drug)
Prednisolone Acetate 1%
Prednisolone Acetate 1% dosed four times daily decreasing to once daily over four weeks.
干预措施: Prednisolone Acetate (Drug)
结局指标
主要结局
Percent Change in Flare at Resolution
时间窗: 2 months
次要结局
未报告次要终点
